Uncategorized Archives - Page 5 of 134

TuesdayJan 07, 2025 8:45 am

Adageis Is Already Positioned to Support Healthcare Shift to a Value-Based Care Model

Transition to a value-based care approach prioritizes quality outcomes over service volume, but calls for a dramatic overhaul of infrastructure, culture and operations. Shifting to value-based care means significant changes in mindset and practice among clinicians, while also disrupting traditional revenue models, creating initial financial risks. Leadership, data analytics, care coordination, and payer collaboration, are key to successful implementation. Adageis is structured to support providers during this transformation, with its unique offering of tools and solutions to simplify the necessary moves, including AI-driven analytics and patient-focused care solutions. The company’s platform is designed to help healthcare organizations optimize care delivery…

MondayDec 30, 2024 8:45 am

Adageis Embracing New Era for Value-Based Care Amid Healthcare System Transition from CMS-HCC V24 to V28

The Centers for Medicare and Medicaid Services’ switch from the Hierarchical Condition Categories model V24 to the modernized V28 brings about an updated disease classification structure that aligns with current healthcare standards. V28 enhances the accuracy of Medicare Advantage payments, impacting conditions like diabetes and dementia. Under the new model, HCC categories rise from 86 to 115, with updated inclusion and exclusion criteria. The transition aligns closely with Adageis’s mission of revolutionizing patient care through innovative value-based care solutions, positioning the company for growth. Adageis aims to improve healthcare delivery by helping providers streamline operations and focus on delivering quality…

ThursdayDec 26, 2024 10:15 am

Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application

The $10 million loan agreement, carrying a 12% interest rate and secured by all assets of Clene, was signed with three lenders affiliated with the company. The funds will be used to repay the remaining $7.9 million debt of an Avenue Capital Group loan, and will improve the company’s cash position, enabling it extra runway to generate additional data to support the new drug application of CNM-Au8 for ALS. The FDA earlier suggested that Clene leverage additional neurofilament light (“NfL”) data from the company’s three Expanded Access Protocols (compassionate use programs) and the HEALEY ALS Platform Trial to support earlier…

FridayDec 13, 2024 1:00 pm

Annovis Bio Inc. (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Year-End Investor Webcast

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders with a comprehensive overview of the company’s 2024 milestones and strategic initiatives for 2025. The full webcast is available here: https://youtu.be/NA3kCUZZIpI. During the webcast, Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, detailed significant progress in the company’s pivotal Phase 3 studies for Buntanetap, its lead drug candidate targeting neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. These studies aim to demonstrate both symptomatic relief and disease-modifying effects, aligning with Annovis Bio’s mission to address the…

FridayDec 13, 2024 12:15 pm

Clene Inc. (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8(R) for ALS

The FDA asked for additional Neurofilament Light (“NfL”) data from the company’s three Expanded Access Protocols to support earlier clinical trial findings. The company has already begun collecting and analyzing this data, with plans to complete the process in Q2 2025 and then submit a New Drug Application (“NDA”) for CNM-Au8 by mid-2025. A follow-up meeting with the FDA will be held early next year to discuss and finalize the statistical analysis plan for the EAP NfL biomarker analyses. The company is meanwhile preparing a confirmatory Phase 3 trial (“RESTORE-ALS”) to evaluate the survival benefit of CNM-Au8 with initial participant…

WednesdayDec 11, 2024 8:45 am

Adageis is Ramping Up Patient Care for All Healthcare Providers and Systems via a Powerful Patented AI-Centric Software

Adageis, with its virtual quality care manager and productivity suite, aims to improve healthcare delivery by helping providers streamline operations and increase revenue through value-based care metrics by implementing its patented ProActive Care Platform. Easily scalable and adaptable, the platform is designed to fit with the electronic medical record systems of any healthcare provider, regardless of size, locations or number of patients. A unique offering in the healthcare technology space, the ProActive Care Platform offers flexible integration, proactive efficiency and advanced predictive analysis capabilities. Adageis is targeting a share of the fast-growing healthcare AI market, which was valued at 19.27…

FridayDec 06, 2024 10:00 am

Cases of Parvovirus B19 Spike in the US

Parvovirus B19, often referred to as the B19 virus, is a seasonal respiratory viral illness that is transmitted through respiratory secretions from an infected individual’s sneezes or coughs, their blood or blood products, or through vertical transmission from a pregnant woman to her baby. Common symptoms include joint pain in adults and slapped cheek rash in kids. In persons with weakened immune systems and blood disorders, infection can lead to a low blood count. The disease may also heighten the risk of miscarriage early in pregnancy. Earlier in August, the CDC issued an advisory on the increase in cases of…

FridayDec 06, 2024 8:45 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against cancer. Calidi Biotherapeutics uses stem cells and cell-enveloping technologies to deliver virotherapy payloads that attack cancers and leave healthy cells untouched. RTNova is designed to address the limitations of traditional virotherapy by offering enhanced targeting, systemic delivery and immune system modulation. Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving further breakthroughs. Emerging therapies, advanced diagnostic…

WednesdayDec 04, 2024 9:30 am

Astiva Health Inc. Expecting to Build Upon This Year’s Performance with Significant Membership Boost in 2025

The company anticipates a 70% increase in membership in the upcoming year, growing the current number of members from 13,000 in June 2024 to 20,000 in 2025. The fourfold increase in membership reflects the growing demand for a change in approach to healthcare that combines innovative personalized strategies with a deep understanding of the served communities. The company has established a strong network of over 12,940 providers, enabling it to offer comprehensive care to its rapidly growing member base, especially in Southern California. Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan, dedicated to reshaping personalized and comprehensive…

TuesdayDec 03, 2024 2:30 pm

Adageis Is ‘One to Watch’

Adageis operates in the rapidly expanding AI healthcare market, projected by Fortune Business Insights to reach $490.96 billion by 2032. The ProActive Care Platform offers seamless integration with existing EMR systems, reducing adoption barriers for healthcare providers. Partnerships with prominent organizations, such as HealthyU Clinics, and its status as an AthenaHealth marketplace partner, demonstrate Adageis’ growing influence in the healthcare sector. The company’s AI-driven predictive analytics enhance patient care and operational efficiency, aligning with the industry’s shift toward value-based care models. Led by a seasoned leadership team with extensive experience in healthcare and technology, Adageis is well-equipped to navigate the evolving healthcare…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Adageis Is Already Positioned to Support Healthcare Shift to a Value-Based Care Model

Adageis Embracing New Era for Value-Based Care Amid Healthcare System Transition from CMS-HCC V24 to V28

Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application

Annovis Bio Inc. (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Year-End Investor Webcast

Clene Inc. (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8(R) for ALS

Adageis is Ramping Up Patient Care for All Healthcare Providers and Systems via a Powerful Patented AI-Centric Software

Cases of Parvovirus B19 Spike in the US

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Astiva Health Inc. Expecting to Build Upon This Year’s Performance with Significant Membership Boost in 2025

Adageis Is ‘One to Watch’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search